Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Attend a group training Schedule a 1-on-1 guided demo Watch a demo video

ABCD Webinar: 40% of men with type 2 diabetes have symptomatic testosterone deficiency – why are we still not finding and treating these men?

About This Webinar

In the fourth of our 2022 ABCD webinar series, please join Dr Bob Ryder and Professor Hugh Jones to discuss symptomatic testosterone deficiency.

40% of men with type 2 diabetes have symptomatic testosterone deficiency. Testosterone deficiency is associated with an adverse effect on cardiovascular risk factors, osteoporosis and psychological wellbeing amongst other issues. Testosterone deficiency is also associated with an increased mortality in type 2 diabetes. Testosterone replacement has been shown to improve insulin resistance, lower HbA1c, lower cholesterol, reduce body weight, reduce mortality and make the patient feel better.

In this webinar we will provide the scientific data behind the information just given and also explain with examples the benefits of the ABCD nationwide audit programme with explanation and encouragement as to why clinicians should change their practice to try and identify their patients with symptomatic testosterone deficiency and enter them into the ABCD worldwide audit of testosterone deficiency in men with type 2 diabetes.

Q& A will follow this presentation

RCP Accreditation has been sought for this webinar. Certificates of attendance will be issued to those who attend the live webinar.

Who can view: Everyone
Webinar Price: Free
Featured Presenters
Webinar hosting presenter

Bob Ryder

Consultant Physician, City Hospital Birmingham & Clinical Lead, Nationwide Audits of New Diabetes Therapies, ABCD
Bob Ryder trained in South Wales and Sheffield. He has worked as a Consultant Physician/Diabetologist/Endocrinologist, City Hospital, Birmingham since 1991. Over the years special interests have included diabetic retinopathy screening; diabetic hypoglycaemia unawareness; diabetic autonomic neuropathy; diabetic impotence; clinical use of IT; treating to target; relative risks and benefits of pioglitazone He leads the ABCD nationwide audits of new therapies and devices – current/imminent audits include SGLT2i, liraglutide, exenatide qw, IDegLira, degludec, FreeStyle Libre, semaglutide, testosterone, closed-loop systems. He is chief investigator of two ABCD Endobarrier studies (https://youtu.be/xRcnMBOdb58, https://youtu.be/y1zm0Scq6YM). Beyond diabetes he is best known as principle author of best-selling "An Aid to the MRCP Short Cases", the 4th-edition of which is the three volume “An Aid to the MRCP PACES”.
VIEW PROFILE
Webinar hosting presenter

Professor Hugh Jones

Honorary Professor of Andrology in the Department of Human Metabolism the University of Sheffield Medical School, Sheffield, UK and Hon. Consultant Endocrinologist at the Royal Hallamshire Hospital, Sheffield
Hugh is Honorary Professor of Andrology in the Department of Human Metabolism the University of Sheffield Medical School, Sheffield, UK and Hon. Consultant Endocrinologist at the Royal Hallamshire Hospital, Sheffield. He is a clinical and laboratory researcher into the role of testosterone in the pathogenesis and treatment of type 2 diabetes and cardiovascular disease. He has also conducted research on the hypothalamic and paracrine control of anterior pituitary hormone secretion, among others. 'Professor Jones is President of the Androgen Society (International). He is also on the European Association of Urology guideline committee for Sexual and Reproductive Health and also the British Society for Sexual Medicine guideline committee for the Management of Testosterone Deficiency. He was also on the International Consultation on Men' Health and Infertility. He was the first to demonstrate the following (1) the high prevalence of symptomatic testosterone deficiency in men with type 2 diabetes, (2) testosterone replacement improves insulin resistance, (3) reduces mortality in hypogonadal men with type 2 diabetes and (4) recently shown testosterone replacement has benefits on quality of life in these men.
VIEW PROFILE
Webinar hosting presenter

Dinesh Nagi

ABCD Ex-Officio Chair
Dr Dinesh Nagi is currently working as an Honorary Consultant in Diabetes and endocrinology at Pinderfields Hospital Wakefield. Having served as Chairman of the ABCD between 2017-2020, he has recently taken up the role of Vice-Chairman of the DCT (Diabetes Care Trust) UK, a charitable trust which works closely with the ABCD. His main interest in diabetes was to promote Integrated Diabetes Care among Primary and Specialist Diabetes Services.
VIEW PROFILE
Recommended
Powered by BigMarker